CDSCO Panel Approves AstraZeneca's Protocol Amendment for Anti-cancer Drug AZD0901 study
Written By : Dr. Divya Colin
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-05-04 12:15 GMT | Update On 2025-05-04 17:05 GMT
New Delhi: The Subject Expert Committee (SEC), functional under the Central Drug Standard Control Organisation (CDSCO), has approved AstraZeneca Pharma India's proposal for protocol amendment of the clinical trial of AZD0901 powder for solution for infusion.
This came after the firm presented protocol Amendment version 2.0 dated 20 Aug 2024, protocol no. D9802C00001.
This is a phase III multi-center, open-label, sponsor-blinded, randomized study of AZD0901 monotherapy compared with the investigator’s choice of therapy in second- or later-line adult participants with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma expressing claudin18.2 (CLARITYGASTRIC01).”
AZD0901 is a drug being developed by AstraZeneca to treat advanced solid tumors, such as pancreatic cancer, gastric cancer, and adenocarcinoma of the gastroesophageal junction. AZD0901 specifically targets and binds to CLDN18. 2 expressed on tumor cells. Upon internalization and the release of MMAE, MMAE targets and binds to tubulin and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CLDN18.
At the recent SEC meeting for oncology, the expert panel reviewed the protocol Amendment version 2.0 dated 20 Aug 2024, protocol no. D9802C00001.
After detailed deliberation, the committee recommended approval of the protocol amendment as presented by the firm.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.